LAUSR

TPS3109Background: Interleukin 8 (IL-8) is a chemokine that has been suggested to play a predominant role in tumor immune escape by promoting an immunosuppressive tumor microenvironment (TME). High levels of serum IL-8 are associated with a poor prognosis in various tumors (Sanmamed, MF, et al. Clin Cancer Res. 2014;20:5697-5707), such as melanoma, non-squamous small cell lung cancer (NSCLC), and renal cell carcinoma, and decreases in serum IL-8 levels have been suggested to be associated with response to anti–PD-(L)1 therapy with nivolumab in a small cohort of pts with melanoma and NSCLC (Sanmamed, MF et al. Ann Oncol. 2017;28:1988-1995). Preclinical studies showed synergetic antitumor activity by combining anti-CXCR2 with anti–PD-1 vs either agent alone in mouse. BMS-986253 is a fully human-sequence IgG1κ anti–IL-8 monoclonal antibody that abrogates signaling through both IL-8 receptors (CXCR1 and CXCR2), resulting in a complete blocking of IL-8 mediated pathway, and as such, can be used to assess the m...